Overwhelming evidence substantiates that CAR-T cells targeting CD117, Siglec-6, CD70, myeloproliferative leukemia protein (MPL), leukocyte immunoglobulin-like receptor-B4 (LILRB4), T cell immunoglobulin and mucin structural domain 3 (TIM-3), membrane-associated folate receptor β (FRβ) and CD44v6 CAR-T cells induce complete remission in immunodeficient mouse xenograft AML models [116–123] (Fig. 2). This evidence concerns the gene MPL and acute myeloid leukemia.